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An  analytical  method  for the  simultaneous  extraction  and  determination  of four  different  groups  of
pharmaceuticals  in  compost  from  the biodegradation  of  biological  infectious  hazardous  wastes  (BIHW)
was  developed  and  successfully  validated.  Compost  samples  were  spiked  with  known  concentrations
of  the  pharmaceuticals  of  interest.  Ultrasonic  extraction  with  an ethyl  acetate  and  methanol  solution
(1:1)  resulted  to  be  effective  for the  extraction  of  eight  target  compounds.  All  the  compounds  were
separated  in a single  gradient  run  by  UHPLC  using  a Zorbax  SB  C18  Agilent  (2.1  ×  50 mm,  1.8  m) column.
Analytes  were  detected  and quantiﬁed  via  multiple  reaction  monitoring  (MRM)  using  an  AB SCIEX  API-
5000TM  triple  quadrupole  with  electrospray  ionization  (ESI)  in positive  mode.  The  optimum  mobile
phase  consisted  of ammonium  formate  (2  mM,  pH 3):  MeOH  (50:50).  Recovery  values  of the  ultrasonic
extraction  for all compounds  were  on the order of  87%  to 113%  with  absolute  deviations  lower than  11%.
The  limits  of  detection  and  quantiﬁcation  for the  eight  pharmaceuticals  were  on  the  order  of  0.66  ng g−1
and  2 ng  g−1 respectively  for all the  pharmaceuticals  analyzed.  These  values  are  lower  than  those  values
reported  in  the  literature.  Suitable  level  of  linearity,  acceptable  limits  of  detection  and  quantiﬁcation,
good  repeatability  and  inter-day  precision,  non-ion  interference,  and  low  matrix  effect  resulted  from  the
validation  of the  analytical  method.  Implementation  of  the analytical  procedure  proposed  in this  research
will contribute  in having  shorter  analysis  time  and  lower  costs  when  working  with  complex  matrices
such  as  compost.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Hospitals are commonly intensive consumers of water and
enerators of biological infectious hazardous wastes (BIHW);
oreover, hospital biological wastes (water and solids) constitute
 very complex matrix, loaded with microorganisms, heavy metals,
harmaceutical products, toxic chemicals, hormonal and radioac-
ive elements [1]. Placenta is considered one of the most frequent
IHW from hospitals and is mainly constituted of biodegradable
rganic matter. Thermophilic Aerobic Treatment has been used to
egrade placentas as an economic and sustainable alternative, not
nly to transform biodegradable waste into nutrient-rich compost
∗ Corresponding author.
E-mail addresses: miganloza@itesm.mx (M.Á. López Zavala),
iliana.reynoso@cimav.edu (L. Reynoso-Cuevas).
ttp://dx.doi.org/10.1016/j.chroma.2015.10.051
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/).that can be used as a fertilizer or soil conditioner, but also to
eliminate, without risk, some organic chemicals such as emerging
pollutants [2,3].
Emerging contaminants are deﬁned as chemicals whose pres-
ence in the environment has recently been detected, and their
ecological and health effects are causing growing concern. They
include pharmaceuticals, personal care products, pesticides and
disinfectants, among others [4]. Contamination by these com-
pounds is still a largely unregulated area, and there is ongoing
debate within the scientiﬁc community regarding which pharma-
ceuticals are included among the priority substances [5].
Pharmaceutically active compounds are of emerging concern
because of their intrinsic biological activity, which may  cause
adverse effects, particularly at chronic exposure [6]. Currently, the
main interest of various research groups is the development of pre-
cise and sensitive analytical methods that allow the quantiﬁcation
of pharmaceuticals and their metabolic and degradation products
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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n different environments at low detection levels. Most of these
ethodologies are based on high-performance liquid chromatog-
aphy (HPLC) and, recently, on tandem mass spectrometry (MS/MS)
ue to its high sensitivity and selectivity [6–10,18]. However, the
imultaneous extraction and determination of different groups
f pharmaceuticals in complex environmental matrices such as
ompost is particularly challenging because of the low detection
imits required, the complex nature of the samples, the different
hemical characteristics of the pharmaceuticals, and the difﬁculty
n extracting and separating these compounds from interference.
ecently, efforts have being conducted to develop methods for the
etermination of pharmaceutical compounds in sewage sludge,
ompost and river sediments. Methods reported are based on the
ltrasonic-assisted extraction and clean-up by SPE [6]; pressurized
iquid extraction (PLE) [21–25], ultrasonic solvent extraction (USE)
25–29] and microwave-assisted extraction (MAE) [30]. However,
ost of them have just been developed and validated for a speciﬁc
ample matrix. Martín et al. [6] reported that extraction by USE is
referred because of its lower cost with respect to the other tech-
iques reported for the extraction of pharmaceuticals from solid
nvironmental samples, PLE and MAE. Moreover, lower degrada-
ion processes occur in USE than in PLE as extraction is carried out
t room temperature instead of at high temperatures of around
00 ◦C reported in PLE methods and, usually, precisions higher than
n MAE  are achieved.
Thus, the aim of this study was to develop and validate a reliable
nd affordable analytical method for the simultaneous extraction
nd determination of four different groups of pharmaceuticals in
ompost obtained from the thermophilic aerobic treatment. The
harmaceuticals were two  non-steroidal anti-inﬂammatory drugs,
etorolac and naproxen, usually administered to humans; two
uoroquinolones, oﬂoxacin and ciproﬂoxacin (which are among
he most commonly prescribed class of antibiotics in Mexico);
wo anti-cancer (antineoplastic or cytotoxic) chemotherapy drugs,
fosfamide and cyclophosphamide; and two -blockers, atenolol
nd propranolol, also called -adrenergic blocking agents, which
reat a variety of conditions, such as high blood pressure, glau-
oma and migraines. The pharmaceuticals of each group were
elected because they are commonly used in Mexico and envi-
onmental and health impacts has been reported. The clustering
as based on the use of the drug and not on the similarity of the
tructure. Table 1 summarizes the characteristics of each pharma-
eutical.
. Experimental methods
.1. Chemicals
Naproxen (NPX) sodium standard (98–100% purity), ketorolac
KET) tris salt standard (≥99% purity), Propranolol (PRO) hydrochlo-
ide (>98% purity), Atenolol (ATE) (>% purity), Ifosfamide (IFO),
ﬂoxacin (OFL) and cyclophosphamide (CFO) monohydrate were
ought from Sigma–Aldrich (Toluca, Mexico) and ciproﬂoxacin
CFL) (>98% purity) was purchased from Fluka Analytical (Stein-
eim, Germany). Methanol was acquired from J.T. Baker (Center
alley, PA, USA). Analytical grade ethyl acetate and ammonium
ormate were provided by Fisher Scientiﬁc (Monterrey, Mexico).
ormic acid (98–100%) was from Merck (Naucalpan, Mexico). Ultra-
ure water was prepared with a Milli-Q water puriﬁcation system
Bedford, MA,  USA). A solution with methanol and ultrapure water
1:1) was prepared and labeled as Solution “A”. Then, 10 mg  mL−1tock solutions for each pharmaceutical were prepared using the
olution “A” and stored at 4 ◦C. Standard solutions at different con-
entrations were daily prepared by using the stock solutions and
he Solution “A”.Fig. 1. Pilot thermophilic aerobic treatment system installed at the San José Hospi-
tal. Monterrey, Mexico.
2.2. Sampling of compost
Thermophilic aerobic treatment was  applied in this study to
transform biological infectious hazardous wastes into nutrient-rich
compost that can be used as a fertilizer or soil conditioner (Fig. 1).
A pilot system was installed and operated at the San José Hospital
in Monterrey, Mexico. Placentas were minced with a food grinder
and incorporated into the reactor of the system that uses saw-
dust as a matrix. The degradation process was  conducted under
the following conditions: matrix moisture content, 50–60%; mixing
frequency, 6 times per day; and temperature, 50–60 ◦C. Compost
samples were collected from the biological reactor and spiked with
pharmaceuticals as described below.
2.3. Analytical methods
2.3.1. Samples preparation
Compost samples were transferred into centrifuge tubes and
spiked with known concentrations of each pharmaceutical stan-
dard solution using micropipettes. Then, high speed vortex (1 min)
was applied to homogenize the distribution and sorption of the
pharmaceuticals into the compost matrix. The spiked samples were
preserved at room temperature for 12 h to ensure pharmaceuticals
sorption.
2.3.2. Extraction method
Volumes of 4 mL  of ethyl acetate and methanol solution (1:1)
were added to the compost samples (50 mg each) spiked with
the eight target pharmaceuticals; next, the mixtures were vortex
for 3 min  and then placed into an ultrasonic bath for 5 min. Cen-
trifugation at 3500 rpm and 4 ◦C, and ultra-freeze at −70 ◦C were
conducted for 5 and 10 min, respectively. The supernatants were
then decanted and evaporated with a gentle stream of nitrogen
until dryness at 45 ◦C, and dissolved again with 500 L of ammo-
nium formate (2 mM,  pH 3) and methanol solution (1:1). High speed
vortex for 20 s, centrifugation at 13,500 rpm and 4 ◦C for 5 min were
applied. Then, the supernatants were ﬁltrated through 0.2 m PTFE
Whatman ﬁlters and the extracts were transferred to 1 mL  vials for
UHPLC–MS/MS analysis.
The extraction efﬁciency, reported as the mean recovery,
was determined based on the analysis of extracts of ﬁve repli-
cates of compost samples spiked with known concentrations of
pharmaceuticals, low (6.0 ng g−1), middle (80.0 ng g−1) and high
(180 ng g−1). The coefﬁcient of variation of the mean recovery must
be lower than 15%.
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Table  1
Characteristics of the pharmaceuticals used in this study.
Pharmaceutical Systematic name Structure Polarity (Log P) Molecular mass (Da)
Anti-inﬂammatory
Ketorolac 5-benzoyl-2,3-dihydro 1H-pyrrolizine-1-carboxylic
acid
2.1 255.09
Naproxen 2-(6-methoxynaphthalen-2-yl) propanoic acid 2.8 230.09
Antibiotics
Oﬂoxacin 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-l-
piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-
benzoxazine-6-carboxylic
acid
2.1 361.14
Ciproﬂoxacin 1-cyclopropyl-6-ﬂuoro-4-oxo-7-(piperazin-1-yl)-
quinoline-3-carboxylic
acid
2.3 331.13
Anticancer
Ifosfamide N-3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-
amine-2-oxide
0.8 260.02
Cyclophosphamide N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-
amine
2-oxide
0.8 260.02
ˇ-Blockers
Atenolol 4-(2-hydroxy-3-isopropylaminopropoxy)-
phenylacetic
acid
0.5 267.15
Propranolol 1-(1-methylethylamino)-3-(1-naphthyloxy)propan-2-
ol
3.0 259.16
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i.3.3. Ultrahigh pressure liquid chromatography and mass
pectrometry method
Detection and quantiﬁcation of the eight target pharmaceuticals
n compost extracts were conducted by UHPLC–MS/MS analysis.
he Acquity Ultra High Pressure LC-system (Waters) consisting
f a degasser, binary gradient pump, auto-sampler (5 ◦C) and a
olumn oven (40 ◦C) was used for separations. All the target com-
ounds were separated in a single gradient run by using a Zorbax SB
18 Agilent (2.1 × 50 mm,  1.8 m)  column. The chromatographic
onditions were ﬂow rate of 250 L min−1 and injection volume
f 5 L. Analytes were detected via multiple reaction monitoring
MRM)  using an AB SCIEX API-5000TM triple quadrupole (Applied
iosystems/MDS SCIEX) with electrospray ionization (ESI) in pos-
tive mode. The mobile phase consisted of ammonium formate(2 mM,  pH 3) and methanol (50:50). The MS  parameters were cad
gas and curtain gas pressures 8 psig and 10 psig, respectively; the
GS1/nebulizer and GS2/turbo GAS ﬂow rates were 45 L min−1 and
30 L min−1, respectively. Ion spray voltage (IS) and source temper-
ature were ﬁxed as 5500 V and 500 ◦C, respectively.
2.3.4. Method validation
Validation was  done based on the guidelines of the International
Conference on Harmonization for Validation of Analytical Proce-
dures [15]. In this study, validation of the method was  conducted
attending the following criteria: linearity, limits of detection (LOD)
and quantiﬁcation (LOQ), and precision as repeatability (intraday
precision) and inter-day precision. Furthermore, carryover, matrix
effects and ion suppression were also evaluated.
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Table 2
Recovered concentrations (RC) and mean recoveries (MR) obtained with the ultrasonic extraction method.
Spiked conc. (ng g−1) KET NPX OFL CFL IFO CFO ATE PRO
RC  (ng g−1)a RC (ng g−1)a RC (ng g−1)a RC (ng g−1)a RC (ng g−1)a RC (ng g−1)a RC (ng g−1)a RC (ng g−1)a
6 6.10 6.14 6.00 6.04 5.24 5.70 6.22 5.66
Std  Dev 0.40 0.60 0.42 0.49 0.23 0.26 0.52 0.47
CV  (%) 6.52 9.70 6.94 8.14 4.48 4.59 8.29 8.25
MRa (%) 101.7 102.3 100.0 100.7 87.3 95.0 103.7 94.3
80  86.10 86.24 84.34 81.18 77.80 79.24 82.68 82.86
Std  3.41 3.88 5.09 6.08 2.21 2.10 8.01 3.83
Dev  CV (%) 3.96 4.50 6.03 7.49 2.84 2.64 9.69 4.63
MRa (%) 107.6 107.8 105.4 101.5 97.3 99.1 103.4 103.6
180  193.34 201.94 198.32 195.20 172.22 177.50 203.44 190.08
Std  Dev 4.09 4.05 2.30 6.96 4.20 4.09 2.32 2.14
CV  (%) 2.12 2.01 1.16 3.57 2.44 2.30 1.14 1.13
108.4
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a Mean of ﬁve replications.
.3.4.1. Linearity. Linearity of the calibration curves for each ana-
yte was veriﬁed by the coefﬁcient of determination (R2 > 0.98) and
he coefﬁcient of variation between response factors (CV < 15%).
o generate the calibration curves, stock solutions of each phar-
aceutical were prepared with Solution “A” to yield samples of
ve different concentrations (1 ng mL−1, 10 ng mL−1, 25 ng ml−1,
0 ng ml−1 and 100 ng mL−1). 50.0 mg  (dry based) compost samples
ere spiked with 100 L of those solutions yielding concentrations
f 2.0 ng g−1, 20.0 ng g−1, 50.0 ng g−1, 100.0 ng g−1 and 200.0 ng g−1;
hen, the pharmaceuticals were extracted as described in the
ection 2.3.2. The extracts were analyzed by UHPLC–MS/MS as
escribed in the Section 2.3.3. Calibration curves for the eight
harmaceuticals were prepared plotting the analytical signal (peak
rea) versus nominal (known) concentration.
.3.4.2. Limits of detection (LOD) and quantiﬁcation (LOQ). The lim-
ts of detection and quantiﬁcation were determined by analyzing
xtracts (by quintuplicate) of compost samples spiked with known
oncentration of pharmaceuticals. The LOD was established as the
inimum concentration that provides a signal to noise ratio greater
han three for the eight pharmaceuticals. The LOQ was set as the
inimum quantiﬁable concentration whose average value is not
eviated beyond ± 20% (CV < 20%) of the nominal (known) concen-
ration for the eight compounds.
.3.4.3. Precision. Precision was considered at two levels, repeata-
ility and inter-day precision. The repeatability was  obtained by
uantifying the concentration of control samples at three different
oncentration levels, namely low 6.0 ng g−1, middle 80.0 ng g−1 and
igh 180.0 ng g−1 in ﬁve replicates of the spiked compost extracts
uring the same day. The inter-day precision was determined by
easuring on two different days, with a daily-prepared standard
urve, the concentration of the control samples at three different
oncentration levels, namely low 6.0 ng g−1, middle 80.0 ng g−1 and
igh 180.0 ng g−1 in four replicates of the spiked compost extracts.
he intraday and inter-day precisions were evaluated in terms of
he coefﬁcient of variation that must be lower than 15%.
.3.4.4. Carryover. The carryover was estimated by injecting a
lank sample extract (from non-spiked compost) after injecting
 spiked compost extract with a pharmaceutical concentration of
00 ng g−1. The acceptance criterion was either the absence of any
ignal or a signal not greater than 10% of noise.
.3.4.5. Matrix effect. The matrix effect was estimated as follows.
hree extracts of non-spiked compost were obtained and then each
xtract was spiked by triplicate with a known concentration of each
harmaceutical at three different concentration levels, namely low
50 ng g−1), middle (100 ng g−1) and high (200 ng g−1). Additionally, 95.7 98.6 113.0 105.6
solutions with the same three concentration levels were also pre-
pared for each pharmaceutical. Concentrations of spiked extracts
and solutions were quantiﬁed and compared. The percentage dif-
ference between corresponding determinations was calculated.
There is signal enhancement if the percentage is positive and sig-
nal suppression if the percentage is negative. A value near to zero
means low matrix effect.
2.3.4.6. Ion interference. The ion interference is useful to detect if
one of the target compounds had some effect (ionization increase
or reduction) over the others. The ion interference was  deter-
mined by quantifying a pharmaceutical (by triplicate) in the
presence of others. Three different concentration levels were used
among the target pharmaceuticals, namely low (50 ng g−1), middle
(100 ng g−1) and high (200 ng g−1). The CV of recovered concentra-
tions should be lower than 15%.
3. Results and discussion
3.1. Optimization of the extraction method
Nine different extraction procedures were evaluated for the
eight pharmaceuticals. First, four extraction protocols developed
for conventional HPLC-techniques, including solid phase extraction
(SPE) and ultrasonic-assisted, and described by Martins et al. [11],
Zhai and Zou [12], Christodoulou et al. [13], and Marachiello et al.
[14]. When the HPLC technique was used, the Martins et al. protocol
[11] was effective for the extraction of the eight pharmaceuticals;
the Christodoulou et al. method [13] for the ciproﬂoxacin, ketoro-
lac, naproxen and propranolol; the Maraschiello et al. procedure
[14] for oﬂoxacin and ciproﬂoxacin; and the Zhai and Zou protocol
[12] resulted not satisfactory for all the target compounds (results
not shown in this paper). When those extraction protocols were
tested with UHPLC–MS/MS, the results were not satisfactory for
all the target pharmaceuticals, even for the Martins et al. method
[11]. This was reasonable because such extraction methods were
developed for conventional HPLC-techniques and when changing
from HPLC to UHPLC analysis, MS  parameters such as ﬂow rates,
ion spray voltage, source temperature, retention time and dwell
times need to be altered to obtain the highest MS  signals possible
[16]. Due to those protocols resulted not satisfactory for all the tar-
get compounds; an exhausted work running great number of tests
with different amounts of samples, extraction solvents, extraction
times, extraction steps and even the use of SPE were evaluated in
order to develop an optimum extraction procedure. The ultrasonic
extraction method described in Section 2.3.3 resulted to be the
optimum procedure for the simultaneous extraction of the eight
pharmaceuticals. Table 2 presents the recovered concentrations,
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Table  3
Mobile phase conﬁgurations evaluated, ions/transitions selected, and multiple reaction monitoring (MRM)  conditions for the analytes detection.
Mobile phase
1 0.1% ammonium acetate + 0.1% acetic acid:ACN:MeOH (50:25:25)
2  Water + 0.1% formic acid:ACN (50:50)
3 MeOH + 0.1% formic acid:ACN (50:50)
4  2mM  ammonium formate (pH 3):MeOH (50:50)
Target compound RTa (min) Precursor
ion (m/z)
Productb ion (m/z) Molecular
formulac
DTd (ms) DPe (V) EPf (V) CCg (V) CCEPh (V)
Ketorolac (KET) 2.83 255.09 105.2, 77.0, 95.1 C7H5O+ 300 100 11 30 10
Naproxen (NPX) 4.97 230.09 185.3, 170.1 C13H13O+ 300 115 10 30 10
Oﬂoxacin (OFL) 0.51 361.14 261.4, 179.1, 219.3,
221.1, 301.2, 344.2
C14H14FN2O2+ 300 142 10 50 10
Ciproﬂoxacin (CFL) 0.55 331.13 231.2, 189.2, 203.3,
314.4
C12H8FN2O2+ 300 150 14 50 10
Ifosfamide (IFO) 1.02 260.02 182.1, 233.3 C5H10ClNO2P+ 300 90 6.5 30 10
Cyclophosphamide (CPO) 1.18 260.02 140.0, 233.3 C4H8Cl2N+ 300 90 6.5 30 10
Atenolol (ATE) 0.43 267.15 145.2, 133.1, 190.0 C10H9O+ 300 140 9 40 10
Propranolol (PRO) 1.11 259.16 155.2, 115.9, 128.8,
165.2, 182.9
C12H11+ 300 130 10 40 10
a RT: Retention time.
b Underlined value: ion transition selected for quantiﬁcation purposes.
c Molecular formula of selected ion.
d DT: dwell time.
e DP: declustering potential.
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ean recoveries and the coefﬁcient of variation of the eight phar-
aceuticals obtained with the ultrasonic extraction method.
Mean recoveries were calculated as the percentage of the
xtracted pharmaceutical compared to the spiked level. As
bserved, the protocol exhibited a low variability response, with
he CV ranging between 1.13% for propranolol at 180 ng g−1 to
.70% for naproxen at 6 ng g−1. The recoveries were in the range of
7% and 113% for all pharmaceuticals. These recoveries are much
reater than those reported by the literature for less complex matri-
es. Martín et al. [6] obtained recoveries of 53% for naproxen and
f 16–80% for other pharmaceuticals in sediment samples. Chen
t al. [17] reported poor absolute recoveries (20.7–75.4%) for 30
ommonly consumed pharmaceuticals in China from samples of
ewatered sewage sludge; they found that these results could be
ue to high matrix effects during the analytical procedure. Marsoni
t al. [8] reported low recovery for oﬂoxacin (37%) that could be
ttributed to the high sensitivity of this compound to the evap-
ration step during their extraction method; in the ultrasonic
ethod proposed in this study, the recovery of oﬂoxacin was  much
reater (100–110%). Shafrir and Avisar [18] obtained recoveries of
1– 31% for sulfonamides and tetracyclines in treated wastewater
ludge and composted biosolids using tandem-solid-phase extrac-
ion cleanup and HPLC–MS/MS with an electrospray ionization.
ased on those results, it is clear that the ultrasonic extraction pro-
edure proposed in this study is an effective and reliable method
o extract pharmaceuticals in complex matrices such as compost.
implicity of the ultrasonic method developed in this study implies
ecessarily low cost of extraction. This is in accordance with those
emarks stated by Martín et al. [6] in the sense that USE is pre-
erred because of its lower cost with respect to the other techniques
eported for the extraction of pharmaceuticals from solid environ-
ental samples.
.2. Optimization of the ultrahigh pressure liquid
hromatography and mass spectrometry methodFour mobile phase conﬁgurations, MRM  conditions and pharma-
euticals’ molecules fragmentation were evaluated for the ﬁnest
erformance of the method. At least two ions/transitions were
elected for each target analyte. But, for quantiﬁcation purposes,the most probable ion product (greater area) was  selected as the
quantiﬁcation ion/transition and the other ions/transitions served
as qualiﬁer ions to conﬁrm the detection of the suspected com-
pound. Table 3 shows the mobile phase conﬁgurations evaluated
and the ions/transitions selected for each compound. From sev-
eral experiments conducted with compost extracts, the optimum
mobile phase resulted to be the solution consisting of ammonium
formate (2 mM,  pH 3) and MeOH (50:50). The optimized ESI and
MS/MS  parameters, including precursor ions, product ions, collision
energy, among others, are all summarized in Table 3.
Fig. 2 shows the ﬁnal retention times obtained for each phar-
maceutical and for the MRM  conditions shown in Table 3. As seen,
the total analysis time is much shorter than conventional HPLC
techniques. The retention factor <1 and some overlapped peaks for
some pharmaceuticals may  suggest deﬁcient separation; however,
due to the UHPLC–MS/MS is a more sensitive method than con-
ventional HPLC techniques, the analytical signals (peak areas) of
the analytes were well detected and quantiﬁcation was accurately
conducted.
3.3. Validation of the method
3.3.1. Linearity
The regression equation and the coefﬁcient of determination
(R2) for each pharmaceutical standard are shown in Table 4 for
the range of 2 ng g−1 to 200 ng g−1. The regression equations were
obtained by least-squares analysis. As seen, the coefﬁcient of deter-
mination for all pharmaceuticals was greater than 0.98, fulﬁlling
the validation criteria of linearity.
Table 4 also shows the recovered concentrations and the mean
recoveries of the ﬁve different concentrations (ﬁve replicates each)
used to generate the calibration curves for the eight pharmaceu-
ticals under study. The coefﬁcient of variation in all cases was
found to be lower than 9.0% thus, the analytical procedure had
a suitable level of linearity in terms of this parameter due to CV
was lower than 15%. The eight pharmaceuticals were detected and
quantiﬁed even at the lowest concentration tested (2 ng g−1), with
mean recoveries for all the pharmaceuticals between 94% and 104%;
therefore, the method proposed in this study is reliable to analyze
the target compounds in compost samples.
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.3.2. Limits of detection (LOD) and quantiﬁcation (LOQ)
A concentration of 0.66 ng g−1 was set as a target LOD in order
o go beyond the values reported in the literature [19]. This value
minimum concentration) provided a signal to noise ratio greater
han three for the eight pharmaceuticals (Table 5). That value was
et as the limit of detection of the eight pharmaceuticals for simul-
aneous analysis. It is clear that the limit of detection could be
mproved for all the pharmaceuticals because the signal to noise
atio is much greater than three. The LOD deﬁned in this research
as much lower than those values reported by the literature,
.4 ng g−1 for oﬂoxacin and 7.2 ng g−1 for ciproﬂoxacin [19]; thus,
he analytical method proposed in this study is suitable for the
etermination of these pharmaceuticals at low concentrations.
able 4
ean recoveries of the ﬁve concentrations used to generate the calibration curves for the
Spiked conc. (ng g−1) KET NPX OFL CFL 
RC  (ng g−1)a RC (ng g−1)a RC (g−1)a RC (ng
2 1.89 2.16 2.04 2.07 
Std  Dev 0.04 0.01 0.03 0.09 
CV  (%) 2.45 0.48 1.26 4.57 
MRa (%) 94.5 108.0 102.0 103.5 
20  20.81 18.90 20.19 20.11 
Std  Dev 0.12 0.26 1.03 0.24 
CV  (%) 0.60 1.33 5.11 1.18 
MRa (%) 104.1 94.5 101.0 100.6 
50  50.27 46.47 48.39 48.02 
Std  Dev 1.20 0.16 0.54 1.09 
CV  (%) 2.38 0.37 1.12 2.27 
MRa (%) 100.5 92.9 96.8 96.0 
100  102.72 99.04 98.97 98.45 
Std  Dev 2.12 3.82 5.12 8.20 
CV  (%) 2.06 3.86 5.18 8.33 
MRa (%) 102.7 99.0 99.0 98.5 
200  196.31 205.37 202.41 203.36
Std  Dev 3.14 3.38 4.66 8.96 
CV  (%) 1.60 1.65 2.30 4.41 
MRa (%) 98.2 102.7 101.2 101.7 
Regression equationb y = 0.9827x +
0.6441
y = 1.0309x −
1.1510
y = 1.0120x −
0.4451
y = 1.0
0.6185
R2 0.9994 0.9993 0.9998 0.9996
a Mean of ﬁve replicates.
b Results are the mean of two calibration curves done in the same day. the eight pharmaceuticals studied.
The limit of quantiﬁcation for the eight pharmaceuticals inves-
tigated in this study is also presented in Table 5. As seen, the
CV and the absolute deviation for all pharmaceuticals were lower
than 11.0% fulﬁlling the acceptance criteria. On the other hand, the
LOQ was  much lower than those values reported in the literature
for less complex matrices such as soil (11.2 ng g−1 and 24.0 ng g−1
for oﬂoxacin and ciproﬂoxacin, respectively) [19], sewage sludge
(24.76 g g−1 for oﬂoxacin) [17], broiler manure (78.52 g g−1 for
doxycycline) [9] and agricultural soil (1.33 g g−1 for doxycycline)
[9]. Therefore, at environmentally relevant concentrations, the
limit of quantiﬁcation determined in this research indicates that the
analytical method developed is suitable for the analyses of complex
matrices such as compost.
 eight pharmaceuticals. Regression curves and coefﬁcient of determination.
IFO CFO ATE PRO
 g−1)a RC (ng g−1)a RC (ng g−1)a RC (ng g−1)a RC (ng g−1)a
1.91 1.93 1.93 2.01
0.04 0.03 0.06 0.10
1.93 1.82 2.98 4.95
95.5 96.5 96.5 100.5
20.55 20.69 20.64 20.35
0.62 0.45 0.35 0.09
3.04 2.17 1.70 0.42
102.8 103.5 103.2 101.8
51.18 49.59 50.42 47.83
0.26 1.36 1.48 1.52
0.52 2.74 2.94 3.17
102.4 99.2 100.8 95.7
100.54 101.78 99.73 102.64
1.17 3.44 1.90 4.50
1.17 3.38 1.91 4.39
100.5 101.8 99.7 102.6
 197.82 198.01 199.28 199.17
0.85 4.32 0.13 6.00
0.43 2.18 0.06 3.02
98.9 99.0 99.6 99.6
166x − y = 0.9877x +
0.4590
y = 0.9910x +
0.3356
y = 0.9946x +
0.2027
y = 0.9999x +
0.0049
 0.9999 0.9998 1.0000 0.9995
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Table 5
Limits of detection and quantiﬁcation for all pharmaceuticals used in this study.
Compound KET NPX OFL CFL IFO CFO ATE PRO
LODa (ng g−1) 0.66 0.66 0.66 0.66 0.66 0.66 0.66 0.66
(signal-to-noise ratio) 26.70 6.12 22.46 108.68 45.04 45.48 269.30 83.78
LOQb (ng g−1) 1.80 2.10 2.15 2.22 2.05 1.77 1.96 1.92
Std.  Dev. 0.06 0.05 0.23 0.10 0.08 0.05 0.14 0.10
CV  (%) 3.42 2.56 10.53 4.30 4.04 2.67 7.01 5.31
Abs.  Dev. (%) 10.22 4.77 7.58 11.19 2.34 11.32 1.84 4.22
a Spiked concentration of 0.66 ng g−1.
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Ab Mean of ﬁve replicates. Spiked concentration: 2.0 ng g−1.
.3.3. Precision
The quality of data obtained from the analyses of pharmaceu-
icals in compost is the major issue of concern. Therefore, good
recision, as repeatability and inter-day precision, is required to
emonstrate the performance efﬁcacy of the method. Table 6
ummarizes the results of the repeatability determination for the
harmaceuticals of interest. Repeatability was obtained from the
nalysis, during the same day, of ﬁve replicates of the three con-
rol concentrations: low (6 ng g−1), middle (80 ng g−1) and high
180 ng g−1). As seen, the coefﬁcient of variation in all cases was
elow 10% and the mean recoveries between 87% and 108%, denot-
ng an acceptable repeatability of the method.
Table 7 summarizes the results of the inter-day precision of
he method for all the target pharmaceuticals. As explained on
ection 2.3.4, inter-day precision was determined by measuring
n two different days, with a daily-prepared standard curve, the
oncentration of the control samples at three different concen-
ration levels, namely low 6.0 ng g−1, middle 80.0 ng g−1and high
80.0 ng g−1 in four replicates of the spiked compost extracts. The
oefﬁcient of variation in all analyses was below 10.22% and the
ean recoveries between 87% and 108%; denoting a satisfactory
nter-day precision. The results of inter-day precision were as good
s those of repeatability for the eight target pharmaceuticals at the
hree concentration levels.
.3.4. Carryover
The results of all tests indicated that carryover of residues inampling/switching valves and late-eluting residues in the column
ere both negligible for all the pharmaceuticals analyzed (data not
hown). Thus, the method performance was good for this type of
omplex biological matrix.
able 6
epeatability of the analytical method for the target pharmaceuticals.
Spiked conc. (ng g−1) KET NPX OFL 
6
RCa (ng g−1) 6.10 6.14 6.0
Std  Dev 0.40 0.60 0.4
CV  (%) 6.52 9.70 6.9
AD  (%) 1.62 2.27 0.0
MR  (%) 101.7 102.3 100.0
80
RCa (ng g−1) 86.09 86.23 84.3
Std  Dev 3.41 3.88 5.0
CV  (%) 3.96 4.50 6.0
AD  (%) 7.62 7.79 5.4
MRa (%) 107.6 107.8 105.4
180
RCa (ng g−1) 193.33 201.92 198.3
Std  Dev 4.09 4.05 2.3
CV  (%) 2.12 2.01 1.1
AD  (%) 7.41 12.18 10.1
MRa (%) 96.7 101.0 99.2
D: absolute deviation.
a Mean of ﬁve replicates3.3.5. Matrix effect
When developing a UHPLC–MS/MS method, matrix effects are
common and an important issue. The effect of co-eluting com-
pounds arising from the matrix can result in signal enhancement
or suppression [16]. Table 8 presents the results of the matrix effect
evaluation. Positive values of the ME  correspond to signal enhance-
ment and negative values correspond to signal suppression. Values
of the ME  near to zero means low matrix effect. The matrix effect
values varied from −11.12% to 6.43%, but most of the values were
lower than an absolute value of 6.0% for all the target pharmaceu-
ticals. Ciproﬂoxacin was  the pharmaceutical with greater matrix
effect. As seen, all the pharmaceuticals presented signal enhance-
ment and suppression at different concentrations. That means that
might be other factors rather than the matrix effect that deviated
the measurements, particularly at the concentration 100 ng g−1.
Nonetheless, in general, it can be considered low matrix effect of
co-extracted substances because most of the ME  values are near to
zero percent. These results are in agreement with those ﬁndings
reported in the literature [16] which establish that matrix effects
are minor or eliminated when using UHPLC–MS/MS.
3.3.6. Ion interference
In this study, the ion interference between the eight pharmaceu-
ticals of interest was evaluated for three different concentration
levels. Due to huge amount of data generated from these tests,
Table 9 summarizes the coefﬁcient of variation of recovery con-
centrations of each compound quantiﬁed in the presence of the
others. As seen, the coefﬁcient of variation was lower than 10.07%
in all cases, which is lower than the acceptance criterion (CV ≤ 15%).
This result indicates that non-ion interference occurred between
the eight pharmaceuticals of interest.
CFL IFO CFO ATE PRO
0 6.03 5.24 5.70 6.22 5.67
2 0.49 0.23 0.26 0.52 0.47
4 8.14 4.48 4.59 8.29 8.25
6 0.55 12.69 4.98 3.64 5.54
 100.5 87.3 95.0 103.7 94.5
3 81.19 77.80 79.25 82.67 82.86
9 6.08 2.21 2.10 8.01 3.83
3 7.49 2.84 2.64 9.69 4.63
1 1.49 2.75 0.94 3.34 3.58
 101.5 97.3 99.1 103.3 103.6
2 195.20 172.22 177.50 203.44 190.07
0 6.96 4.20 4.09 2.32 2.14
6 3.57 2.44 2.30 1.14 1.13
8 8.45 4.32 1.39 13.03 5.60
 97.6 86.1 88.8 101.7 95.0
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Table 7
Inter-day precision of the analytical method for the target pharmaceuticals.
Spiked conc. (ng g−1) KET NPX OFL CFL IFO CFO ATE PRO
6
RCa (ng g−1) 6.50 5.35 6.36 6.27 5.90 6.11 5.61 6.19
Std  Dev 0.37 0.17 0.23 0.52 0.44 0.37 0.30 0.39
CV  (%) 5.70 3.25 3.61 8.31 7.53 6.10 5.40 6.34
AD  (%) 8.41 10.79 6.03 4.57 1.73 1.90 6.57 3.19
MRa (%) 108.3 89.2 106.0 104.5 98.3 101.8 93.5 103.2
80
RCa (ng g−1) 84.91 82.47 80.41 81.30 79.07 80.66 75.62 83.37
Std  Dev 2.98 4.10 6.01 5.64 3.03 3.21 4.31 4.34
CV  (%) 3.51 4.97 7.48 6.94 3.83 3.99 5.70 5.26
AD  (%) 6.13 3.09 0.52 1.62 1.16 0.82 5.47 4.21
MRa (%) 106.1 103.1 100.5 101.6 98.8 100.8 94.5 104.2
180
RCa (ng g−1) 186.47 195.20 181.30 186.73 174.20 180.02 184.12 186.86
Std  Dev 7.20 11.46 13.03 19.08 4.34 3.78 17.31 5.66
CV  (%) 3.86 5.87 7.19 10.22 2.49 2.10 9.40 3.03
AD  (%) 3.60 8.45 0.72 3.74 3.22 0.01 2.29 3.81
MRa (%) 93.2 97.6 90.7 93.4 87.1 90.0 92.1 93.4
AD: absolute deviation.
a Mean of four replicates.
Table 8
Matrix effect based on three different concentrations.
KET NPX OFL CFL IFO CFO ATE PRO
NC (ng g−1)a 50.00 50.00 50.00 50.00 50.00 50.00 50.00 50.00
SSC  (ng g−1)b 51.12 46.35 48.78 48.79 51.36 50.55 49.37 48.90
SEC  (ng g−1)c 49.42 46.59 48.01 47.25 50.99 48.63 51.47 46.76
ME  (%) −3.31 0.52 −1.57 −3.16 −0.73 −3.80 4.24 −4.39
NC  (ng g−1) 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
SSC  (ng g−1) 104.21 101.74 102.59 104.24 101.37 104.21 101.07 105.83
SEC  (ng g−1) 101.22 96.33 95.35 92.65 99.71 99.35 98.38 99.46
ME  (%) −2.87 −5.32 −7.06 −11.12 −1.64 −4.67 −2.66 −6.02
NC  (ng g−1) 200.00 200.00 200.00 200.00 200.00 200.00 200.00 200.00
SSC  (ng g−1) 194.09 202.97 199.11 197.02 197.22 194.95 199.19 194.92
SEC  (ng g−1) 198.53 207.77 205.70 209.69 198.43 201.06 199.37 203.42
ME  (%) 2.29 2.36 3.31 6.43 0.61 3.13 0.09 4.36
I
l
a
f
i
a
T
C
Ca NC: nominal concentration.
b SSC: measured standard solution concentration.
c SEC: measured spiked extract concentration.
As shown in previous sections, all the acceptance criteria of the
nternational Conference on Harmonization for Validation of Ana-
ytical Procedures [15] were fulﬁlled satisfactory; therefore, the
nalytical method developed and validated in this paper is reliable
or accurate measurements of different groups of pharmaceuticals
n complex matrices such as compost when UHPLC–MS/MS is used
nd concentrations are on the order of ng g−1 of dry compost.
able 9
oefﬁcient of variation (%) of recovery concentrations of each compound quantiﬁed in th
Quantiﬁed compound SCa In presence of
KET NPX OF
KET 200.0
SC – 200.0 20
CV  9.03 2.6
NPX 100.0
SC 100.0 – 10
CV  2.52 5.2
OFL 100.0
SC 100.0 100.0 –
CV  3.51 7.70 
CFL 50.0
SC 50.0 50.0 50
CV  0.54 10.07 6.0
IFO 100.0
SC 100.0 100.0 10
CV  0.65 1.75 6.6
CFO 100.0
SC 100.0 100.0 10
CV  3.51 7.70 3.8
ATE 100.0
SC 100.0 100.0 10
CV  3.65 0.11 4.0
PRO 100.0
SC 100.0 100.0 10
CV  4.40 0.73 0.7
V: Coefﬁcient of variation (%).
a SC: Spiked concentration (ng g−1).It is important to remark that the guidelines of the Interna-
tional Conference on Harmonization for Validation of Analytical
Procedures are commonly used for product purity tests in phar-
maceutical industry rather than for the environment monitoring;
however, some tests are similar in validation [20]. Conventional
analytical methods for environment monitoring purpose com-
monly use internal standards or surrogates to get accuracy;
e presence of the others.
L CFL IFO CFO ATE PRO
0.0 200.0 200.0 200.0 200.0 200.0
5 3.55 3.67 1.55 3.29 6.07
0.0 100.0 100.0 100.0 100.0 100.0
3 6.22 0.06 0.23 2.80 9.37
100.0 100.0 100.0 100.0 100.0
3.55 3.83 1.08 0.20 6.79
.0 – 50.0 50.0 50.0 50.0
9 1.50 2.17 0.58 5.73
0.0 100.0 – 100.0 100.0 100.0
1 6.62 9.05 1.53 2.84
0.0 100.0 100.0 – 100.0 100.0
3 3.55 1.08 0.20 6.79
0.0 100.0 100.0 100.0 – 100.0
0 9.08 1.72 1.11 0.52
0.0 100.0 100.0 100.0 100.0 –
6 3.75 0.05 2.89 0.44
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evertheless, they are time consuming and increase the cost of the
nalysis. Furthermore, the validation procedures of the ICH HAR-
ONISED TRIPARTITE GUIDELINE do not consider them because
his methodology includes parameters to evaluate the extraction
fﬁciency, the matrix effect and the ion interference. With the ana-
ytical method proposed in this study, analysis time and costs are
educed and an acceptable accuracy is achieved. Undoubtedly more
esearch is needed to improve the chromatographic separation
nd validate the proposed analytical method for other pharma-
euticals and other matrices. Nonetheless, the protocol proposed
n this study could be applied for pharmaceuticals with similar
tructure and positive ionization. As seen, most of the pharmaceu-
icals used in this study were different in structure because the
election was based on the use of the drug and not on the simi-
arity of the structure; however, the ionization of all of them was
n positive mode and consequently were detected and quantiﬁed
imultaneously. This in an important issue to take into consider-
tion in the future application of the protocol developed in this
tudy.
This manuscript deals with the development and validation of
n extraction, detection and quantiﬁcation method via the appli-
ation of the ICH HARMONISED TRIPARTITE GUIDELINE criteria,
ather than application of the method to evaluate the pres-
nce of the target pharmaceuticals in compost. The application
f the method was out of the scope of this paper. However,
t is important to remark that the compost used in this study
as free of such pharmaceuticals and their metabolites. The
hermophilic aerobic biodegradation is an effective process not
nly to degrade biological infectious hazardous wastes, but also,
o degrade micropollutants such pharmaceuticals and hormones
ontained in placentas and in other pathological wastes from hos-
itals.
. Conclusions
An UHPLC–MS/MS analytical method for the simultaneous
xtraction and determination of four different groups of pharma-
euticals in compost from biological infectious hazardous wastes
as developed and validated. The method fulﬁlled the valida-
ion criteria of the International Conference on Harmonization
or Validation of Analytical Procedures. Suitable level of linearity,
cceptable limits of detection and quantiﬁcation, good repeatabil-
ty and inter-day precision, non-ion interference, and negligible
arryover and matrix effect were obtained. Ultrasonic extraction
esulted to be an effective method for the simultaneous extrac-
ion of the eight pharmaceuticals analyzed. High recoveries, greater
han those reported on the literature for similar matrices were
btained (87–113%, for all the compounds). The UHPLC–MS/MS
nalytical procedure proposed was sensitive and effective to detect
nd quantify simultaneously all the pharmaceuticals. The limit
f detection of the method (0.66 ng g−1 for all the pharmaceuti-
als) was lower than those values reported by other researchers
or similar and simpler matrices. The LOQ was  on the order of
 ng g−1 for all the pharmaceuticals, much lower than those val-
es reported in the literature for less complex matrices such as soil
11.2 ng g−1 and 24.0 ng g−1 for oﬂoxacin and ciproﬂoxacin, respec-
ively), sewage sludge (24.76 g g−1 for oﬂoxacin), broiler manure
78.52 g g−1 for doxycycline) and agricultural soil (1.33 g g−1 for
oxycycline).
Regarding the application of the analytical method, in the
ontext of routine work at any environmental laboratory, its imple-
entation will contribute in having suitable compounds recovery,
cceptable levels of detection and quantiﬁcation, minimum matrix
ffect, shorter analysis time and lower costs when working with
omplex matrices such as compost.
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